T-cell Therapy Market

T-cell Therapy Market by Modality (Research and Commercialized), Types (CAR T-cell Therapy, Tumor Infiltrating Lymphocytes-based, and T-cell Receptor Based), Indications (Hematologic Malignancies [Lymphoma, Leukemia, and Myeloma], Solid Tumors [Melanoma, Brain & Central Nervous System, Liver Cancer, and Others], and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1499
  • Author: Growth Market Reports
  • Rating: 4.7
  • Total Reviews: 2
  • No. Of Pages: 173
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global T-cell therapy market size was valued at USD 4.56 billion in 2020 and is estimated to surpass USD 19.85 billion by 2028 expanding at a CAGR of 20.1% during the forecast period, 2021–2028. The growth of the market is attributed to the increased research and development activities for tumor-related programs along with rising numbers of approvals of cancer diagnostic as well as treatment devices.

T-cell Therapy Market Key Takeaways

T-cells are basically the pillars of the immune system that are acting the role of stimulating the immune response, which help to kill the cells infected by pathogens. The T-cell therapy is a technique in which the T-cells are extracted from the blood and then they are attached with a specific artificial receptors to their surface, and are administered back to the patient’s body. These modified cells then achieve the ability to recognize the specific pathogens or cells according to the receptors applied to them. This results in the development of improved immunity towards the pathogen or diseases. This technique is getting popular as it holds a potential for providing better immunity to the humans from major diseases infection.

The therapy is widely applied in cancer treatment and is increasingly adopted as cancer has emerged as one of the major causes of death in the world annually. According to evaluations from the International Agency for Research on Cancer (IARC), the global cancer cases is expected to rise to 27.5 million new cancer cases and 16.3 million deaths by 2040, globally. As per the study by World Health Organization (WHO), the new cancer cases is going to rise from 18 million in 2018 to 29.4 million by 2040. These rising numbers suggest that the T-cell therapy market has a huge potential to grow in cancer treatment. For instance, the introduction of the chimeric antigen receptor T-cells (CAR T-cells) is a novel technique for the cancer treatment and several research activities are being under process to improve the therapy.

Meanwhile, the T-cell method covers different sorts of diseases and has its extensive applications in treatment of several diseases especially tumors but has extended for the COVID-19 patient treatment. This has led to boost the overall market growth. In September 2020, the US Food and Drug Administration (FDA) has approved the investigational new drug (IND) for ALVR109, which is a type of T-cell therapy to treat COVID-19 patients.

Market Trends, Drivers, Restraints, and Opportunities

  • Rising investments, research activities, and increasing approvals of cancer therapy methods and treatment devices are driving the market growth.
  • The COVID-19 pandemic has opened an opportunity for research in the field of viral infections as the major players started investing in the viral infection segment, which is expected to propel the market revenue.
  • Rapid growth in number of clinical trials for CAR-T-cell globally and extensive research for the expansion of its applications are projected to bolster the market growth in the coming years.
  • Lack of awareness of the advanced therapy and tumor treatment methods among a large number of the population from developing nations is proving to be a restraining factor for the market growth.
  • Poor quality of research and development in poor economic nations along with lack of substantial governments’ interest due to the high expense the market is likely to hinder the overall market expansion.

Scope of the Report

The report on the global T-cell therapy market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

T-cell therapy Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Modality (Research and Commercialized), Types (CAR T-cell Therapy, Tumor Infiltrating Lymphocytes-based, and T-cell Receptor Based), Indications (Hematologic Malignancies [Lymphoma, Leukemia, and Myeloma], Solid Tumors [Melanoma, Brain & Central Nervous System, Liver Cancer, and Others], and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Novartis AG; Celgene Corp.; TCR2 Therapeutics Inc.; Bluebird Bio Inc.; Sorrento Therapeutics; Gilead Sciences, Inc.; Fate Therapeutics; Merck KGaA; Pfizer Inc.; and Amgen

 

Market Segment Insights

Research segment is expected to dominate the market

Based on modality, the global T-cell therapy market is bifurcated into research and commercialized. The research segment is expected to dominate the market during the forecast period and held a revenue share of more than 67.5% of the global market in 2020. The segment growth is mainly due to the great number of products in clinical phase along with high investments for research and development by the major players of the market. For instance, Mayo Clinic are carrying out CAR-T therapy programs to support the cancer management method. Moreover, the rising governments’ approvals for various research activities of the key regional players across major economies such as Australia, major countries of EU, Japan, Canada, and other nations play an important role for the segment growth.

CAR-T therapy segment is estimated to proliferate a considerable pace

On the basis of types, the market is divided into CAR T-cell therapy, tumor infiltrating lymphocytes-based, and T-cell receptor based. The CAR-T therapy segment is estimated to proliferate a considerable pace attributing to the significant increase in number of clinical trials of CAR-T along with rising investment from major players of the market in the segment. Moreover, the growing gene therapy market and rising investments in the gene therapy are proving to key factors for the successful growth of the segment.

Meanwhile, the T-cell receptor-based segment is projected to exhibit a robust CAGR indicating positive growth during the forecast period owing to potential expansion and wide application of the therapy in the solid tumors treatment. The treatment of melanoma is the key section for this segment which is under the watch of several major players.

T-cell Therapy Market by Types

Hematologic malignancies is expected to register a high CAGR

Based on the indications, the market is classified as hematologic malignancies, solid tumors, and others. The hematologic malignancies segment is further segmented into lymphoma, leukemia, and myeloma. The solid tumors segment is also sub-divided into melanoma, brain & central nervous system, liver cancer, and others. The Hematologic malignancies segment is expected to register a high CAGR during the forecast period owing to the wide use of CAR-T therapy for the treatment of hematologic malignancies. The segment held more than 47.5% of revenue share in 2020 and the trend is expected to continue in the coming years. The solid tumors segment, on the other hand, is projected to expand at a healthy growth rate in the near future due to the high saturation the hematologic malignancies market and the presence of major players opting to explore the untapped solid tumor segment.

North America is anticipated to constitute a major market share

In terms of regions, the global T-cell therapy market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a major market share in the coming year and accounted for a revenue share of nearly 40% in 2020. The regional market growth can be attributed to factors such as advanced research techniques, large number of clinical trials being under process especially in the US, as well as the presence of high skilled professionals. Additionally, expansion of significant number of medical centers providing CAR-T cell therapies are likely to bolster the market growth in the region. On the other hand, the market of Asia Pacific is expected to exhibit promising growth in the coming future due to the high number of population suffering from cancer and increasing number of clinical trials for development of new therapies. Moreover, government’s interest in the therapy is propelling the market in the region.

T-cell Therapy Market by Regions

Segments

Segments Covered in the Report
The global T-cell therapy market has been segmented on the basis of

Modality

  • Research
  • Commercialized

Types

  • CAR T-cell Therapy
  • Tumor Infiltrating Lymphocytes-based
  • T-cell Receptor Based

Indications

  • Hematologic Malignancies
    • Lymphoma
    • Leukemia
    • Myeloma
  • Solid Tumors
    • Melanoma
    • Brain & Central Nervous System
    • Liver Cancer
    • Others
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Novartis AG
  • Celgene Corp.
  • TCR2 Therapeutics Inc.
  • Bluebird Bio Inc.
  • Sorrento Therapeutics
  • Gilead Sciences, Inc.
  • Fate Therapeutics
  • Merck KGaA
  • Pfizer Inc.
  • Amgen

Competitive Landscape

Key players competing in the global T-cell therapy market are Novartis AG; Celgene Corporation; TCR2 Therapeutics Inc.; Bluebird Bio Inc.; Sorrento Therapeutics; Gilead Sciences, Inc.; Fate Therapeutics; Merck KGaA; Pfizer Inc.; and Amgen.

In August 2017, Novartis developed Kymriah, a CAR-T based therapy for treatment of leukemia. In another event, Gilead Sciences Pharma developed Yescarta, a CAR-T based therapy for treatment of patients with lymphoma, which was approved by the US FDA in March 2021. In collaboration with GlaxoSmithKline, Adaptimmune Company is focused on TCR therapy for melanoma.

T-cell Therapy Market by Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. T-cell Therapy Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. T-cell Therapy Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. T-cell Therapy Market - Supply Chain
  4.5. Global T-cell Therapy Market Forecast
     4.5.1. T-cell Therapy Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. T-cell Therapy Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. T-cell Therapy Market Absolute $ Opportunity
5. Global T-cell Therapy Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. T-cell Therapy Market Size and Volume Forecast by Types
     5.3.1. CAR T-cell Therapy
     5.3.2. Tumor Infiltrating Lymphocytes-based
     5.3.3. T-cell Receptor Based
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global T-cell Therapy Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. T-cell Therapy Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global T-cell Therapy Demand Share Forecast, 2019-2026
7. North America T-cell Therapy Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America T-cell Therapy Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America T-cell Therapy Market Size and Volume Forecast by Types
     7.4.1. CAR T-cell Therapy
     7.4.2. Tumor Infiltrating Lymphocytes-based
     7.4.3. T-cell Receptor Based
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America T-cell Therapy Demand Share Forecast, 2019-2026
8. Latin America T-cell Therapy Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America T-cell Therapy Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America T-cell Therapy Market Size and Volume Forecast by Types
     8.4.1. CAR T-cell Therapy
     8.4.2. Tumor Infiltrating Lymphocytes-based
     8.4.3. T-cell Receptor Based
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America T-cell Therapy Demand Share Forecast, 2019-2026
9. Europe T-cell Therapy Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe T-cell Therapy Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe T-cell Therapy Market Size and Volume Forecast by Types
     9.4.1. CAR T-cell Therapy
     9.4.2. Tumor Infiltrating Lymphocytes-based
     9.4.3. T-cell Receptor Based
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe T-cell Therapy Demand Share Forecast, 2019-2026
10. Asia Pacific T-cell Therapy Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific T-cell Therapy Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific T-cell Therapy Market Size and Volume Forecast by Types
     10.4.1. CAR T-cell Therapy
     10.4.2. Tumor Infiltrating Lymphocytes-based
     10.4.3. T-cell Receptor Based
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific T-cell Therapy Demand Share Forecast, 2019-2026
11. Middle East & Africa T-cell Therapy Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa T-cell Therapy Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa T-cell Therapy Market Size and Volume Forecast by Types
     11.4.1. CAR T-cell Therapy
     11.4.2. Tumor Infiltrating Lymphocytes-based
     11.4.3. T-cell Receptor Based
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa T-cell Therapy Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global T-cell Therapy Market: Market Share Analysis
  12.2. T-cell Therapy Distributors and Customers
  12.3. T-cell Therapy Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Novartis AG
     12.4.2. Celgene Corp.
     12.4.3. TCR2 Therapeutics Inc.
     12.4.4. Bluebird Bio Inc.
     12.4.5. Sorrento Therapeutics
     12.4.6. Gilead Sciences, Inc.
     12.4.7. Fate Therapeutics
     12.4.8. Merck

Segments Covered in the Report
The global T-cell therapy market has been segmented on the basis of

Modality

  • Research
  • Commercialized

Types

  • CAR T-cell Therapy
  • Tumor Infiltrating Lymphocytes-based
  • T-cell Receptor Based

Indications

  • Hematologic Malignancies
    • Lymphoma
    • Leukemia
    • Myeloma
  • Solid Tumors
    • Melanoma
    • Brain & Central Nervous System
    • Liver Cancer
    • Others
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Novartis AG
  • Celgene Corp.
  • TCR2 Therapeutics Inc.
  • Bluebird Bio Inc.
  • Sorrento Therapeutics
  • Gilead Sciences, Inc.
  • Fate Therapeutics
  • Merck KGaA
  • Pfizer Inc.
  • Amgen

Key players competing in the global T-cell therapy market are Novartis AG; Celgene Corporation; TCR2 Therapeutics Inc.; Bluebird Bio Inc.; Sorrento Therapeutics; Gilead Sciences, Inc.; Fate Therapeutics; Merck KGaA; Pfizer Inc.; and Amgen.

In August 2017, Novartis developed Kymriah, a CAR-T based therapy for treatment of leukemia. In another event, Gilead Sciences Pharma developed Yescarta, a CAR-T based therapy for treatment of patients with lymphoma, which was approved by the US FDA in March 2021. In collaboration with GlaxoSmithKline, Adaptimmune Company is focused on TCR therapy for melanoma.

T-cell Therapy Market by Key Players

Buy Report